Our lead drug candidate, obefazimod, has generated promising results in Phase IIa and Phase IIb clinical trials for the treatment of ulcerative colitis, a chronic inflammatory bowel disease, and in a Phase IIa clinical trial in rheumatoid arthritis.
Interview with the Founder and Chairman, the CEO, and the EVP and CFO: Abivax SA (OTCMKTS:AAVXF) twst.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from twst.com Daily Mail and Mail on Sunday newspapers.